跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
REMINYL 16 mg CAPSULAS DURAS DE LIBERACION PROLONGADA - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
REMINYL 16 mg CAPSULAS DURAS DE LIBERACION PROLONGADA
Approved
STANDARD
REMINYL 16 mg CAPSULAS DURAS DE LIBERACION PROLONGADA
Janssen Cilag Pharmaceutical S.A.C.I.
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Jan 12, 2022
Approval ID
3071c292a5a6437a
Company
Janssen Cilag Pharmaceutical S.A.C.I.
Type
Standard
Approval Details
Approval Id
3071c292a5a6437a
Drug Cima Aemps Name
REMINYL 16 mg CAPSULAS DURAS DE LIBERACION PROLONGADA
Register Number
31822-12-05-2015
Holder Company Name
Janssen Cilag Pharmaceutical S.A.C.I.
Marketing Company Name
Elam Pharma Labs S.L.
Authorization Date
2022-01-12
Dosage Form
CÁPSULA DURA DE LIBERACIÓN PROLONGADA
Dose
16 mg
Route Of Administration
VÍA ORAL
Prescription Type
Diagnóstico Hospitalario
Commercialized
No
Company Name
Janssen Cilag Pharmaceutical S.A.C.I.
Active Ingredients
GALANTAMINA HIDROBROMURO
20,51 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Jan 12, 2022
Approval ID
3071c292a5a6437a
Type
Standard
Back to CIMA-AEMPS Approvals
